BEONE MEDICINES(06160.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at USD 227.36 million, YoY increase of 17802.13%
In terms of profitability, BEONE MEDICINES Gross Profit changed from USD 952.28 million in the same period last year to USD 1.35 billion in the current period, increased by USD 393.95 million; gross profit margin changed from 85.23% in the same period last year to 88.95% in the current period, increased by 3.72 percentage points; net profit changed from USD 1.27 million in the same period last year to USD 227.36 million in the current period, increased by USD 226.09 million; net profit margin changed from 0.11% in the same period last year to 15.02% in the current period, increased by 14.91 percentage points.
In terms of earnings quality, BEONE MEDICINES Operating Profit changed from USD 11.1 million in the same period last year to USD 249.9 million in the current period, increased by USD 238.8 million; Operating Profit Margin changed from 0.99% in the same period last year to 16.51% in the current period, increased by 15.52 percentage points; Net Cash Flow from Operating Activities changed from cash inflow of USD 44.08 million in the same period last year to cash inflow of USD 201.34 million in the current period, increased by USD 157.25 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from 3.95% in the same period last year to 13.3% in the current period, increased by 9.36 percentage points.
In terms of financial soundness, BEONE MEDICINES Debt-to-Asset Ratio changed from 40.09% in the same period last year to 44.35% in the current period, increased by 4.25 percentage points; Total Equity changed from USD 3.5 billion in the same period last year to USD 4.76 billion in the current period, increased by USD 1.26 billion; Cash and Cash Equivalents changed from USD 2.531 billion in the same period last year to USD 4.853 billion in the current period, increased by USD 2.32 billion.
In terms of R&D investment focus, BEONE MEDICINES R&D Expenses changed from USD 481.89 million in the same period last year to USD 541.22 million in the current period, increased by USD 59.34 million; R&D to Total Revenue Ratio changed from 43.13% in the same period last year to 35.76% in the current period, decreased by 7.37 percentage points.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
